Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vunakizumab Combined With Recaticimab in Plaque Psoriasis and Dyslipidemia
NCT07373847Phase 4
Key facts
- Status
- Not yet recruiting
- Start
- Jan 2026
- Primary completion
- Jun 2027
- Sponsor
- Xiangya Hospital, Central South University
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Drugs
- recaticimab
- Conditions
- plaque psoriasisdyslipidemia
01
Overview
Phase 4, randomised trial in plaque psoriasis and dyslipidemia comparing Vunakizumab + Recaticimab with Vunakizumab + Placebo (2 arms). Primary endpoint: Psoriasis Area and Severity Index 100 response rate at 16 weeks. Planned start Jan 2026; status: not yet recruiting.
02
Design
2 arms- Study design
- Randomized
Vunakizumab + Recaticimab
Vunakizumab 240 mg SC at Weeks 0, 2, 4, then q4w + Recaticimab 150 mg SC q4w or 300 mg q8w.
Vunakizumab + Placebo
Vunakizumab 240 mg SC at Weeks 0, 2, 4, then q4w + Placebo 150 mg SC q4w or 300 mg q8w.
03
Who it enrols
Adults aged 18-75 with moderate-to-severe plaque psoriasis (PASI >=10, BSA >=10%, PGA >=3) and dyslipidemia (LDL-C 2.6-4.9 mmol/L, TG <5.6 mmol/L, 10-year ASCVD risk <10%), without severe cardiovascular disease, uncontrolled hypertension, severe renal/hepatic impairment, or active infections.
04
Endpoints
Primary
Psoriasis Area and Severity Index 100 response rate
Beyond the preview
Go deeper on NCT07373847.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07373847.